2024
Sex differences in patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites.: Sex Differences in Ascites Burden Perception.
Wong F, Reddy K, Tandon P, Lai J, Garcia-Tsao G, O'Leary J, Biggins S, Vagas H, Thacker L, Kamath P, Bajaj J. Sex differences in patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites.: Sex Differences in Ascites Burden Perception. The American Journal Of Gastroenterology 2024 PMID: 39601412, DOI: 10.14309/ajg.0000000000003251.Peer-Reviewed Original ResearchPatient-centered carePhysical functioning componentHealth related QoLPatient-reported metricsPatient-reported outcomesCo-morbiditiesQuality of lifePhysical activityBurden perceptionEmotional HRQoLStudy assessed sex differencesSex differencesAlcohol related liver diseaseFrailty measuresDaily functioningFunctional statusHRQoLFrailty scoreDaily activitiesLiver diseaseLived experienceEnd-stage liver diseaseWomenActivity indexMedian MELD-NaViral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
Hsu C, Wang L, Maestri E, Jacob A, Do W, Mayo S, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang X, Schnabl B. Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology 2024 PMID: 39325984, DOI: 10.1097/hep.0000000000001046.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderHigher Child-Pugh scoreSerological profileAntibody responseAssociated with very high mortalityUse disorderDecompensation of liver diseaseChild-Pugh scoreActive alcohol useNinety-day mortalityAssociated with decompensationMulticenter observational studyViral antibody responseMonths of diagnosisAntibody repertoireSera of patientsMultiorgan dysfunctionPoor prognosisNinety-daySerological biomarkersHealthy controlsPatient seraLiver diseaseAntibody targetingFaecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Kreimeyer H, Gonzalez C, Fondevila M, Hsu C, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez D, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut 2024, gutjnl-2024-332730. PMID: 39033024, DOI: 10.1136/gutjnl-2024-332730.Peer-Reviewed Original ResearchAlcohol-associated hepatitisShort-term survivalMulticentre cohortSeverity of ALDAlcohol-associated liver diseaseIndependent validation cohortInduce gut dysbiosisNon-invasive markerAlcohol-use disordersNeutrophil degranulationPrediction of short-term survivalPrognostic effectHepatic neutrophilsValidation cohortBacterial translocationNeutrophil granulesMPO levelsLiver diseaseFecal biomarkersTandem mass tagPatientsGut dysbiosisLiver damageDisease severityNeutrophilsCHAPTER 1 Introduction
Ortiz G, Garcia-Tsao G. CHAPTER 1 Introduction. 2024, 1-6. DOI: 10.1016/b978-0-323-87479-3.00010-7.ChaptersChronic liver diseasePortal hypertensionSustained liver injurySignificant portal hypertensionHealth care utilizationHepatic vein catheterizationStaging of fibrosisBurden of diseaseMost complicationsLiver injuryCare utilizationLiver diseaseVein catheterizationCirrhotic stageLiver stiffnessInvasive proceduresTime of interpretationDiffuse depositionSignificant causeAge groupsNoninvasive meansFibrous tissueSmall riskInterobserver variabilityGold standard
2023
The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease
Jirapinyo P, Thompson C, Garcia-Tsao G, Zucker S, Ryou M. The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Endoscopy 2023, 56: 56-62. PMID: 37532114, DOI: 10.1055/a-2146-8857.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseEndoscopic gastric plicationAdvanced chronic liver diseaseFatty liver diseasePortosystemic pressure gradientChronic liver diseaseLiver diseaseTotal weight lossGastric plicationNoninvasive testsBaseline median body-mass indexMedian body mass indexPercent total weight lossWeight lossProportion of patientsProspective pilot studyBody mass indexLiver stiffness measurementWeight loss proceduresGoal of therapyHepatic decompensationSecondary outcomesPrimary outcomeMass indexPatientsControversies regarding albumin therapy in cirrhosis.
Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis. Hepatology 2023 PMID: 37540192, DOI: 10.1097/hep.0000000000000521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpontaneous bacterial peritonitisBacterial peritonitisAcute kidney injuryLarge-volume paracentesisSerum albumin levelChronic liver diseaseUse of albuminHepatorenal syndromeAdvanced cirrhosisAlbumin infusionKidney injuryAlbumin therapyAlbumin levelsAlbumin useProinflammatory stateLiver diseasePatient selectionVolume overloadPoor outcomeHigh oxidative stressCirrhosisPathophysiological relevanceOxidative stressPeritonitisAlbuminMedications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol useMELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
Díaz L, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde M, Perez D, Gómez J, Escarate R, Villalón A, Ramírez C, Hernandez-Tejero M, Zhang W, Qian S, Simonetto D, Ahn J, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Salazar P, Skladaný L, Bystrianska N, Clemente-Sanchez A, Villaseca-Gómez C, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Castro-Sanchez S, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Louvet A, García-Tsao G, Roblero J, Abraldes J, Shah V, Kamath P, Arrese M, Singal A, Bataller R, Arab J. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports 2023, 5: 100727. PMID: 37456675, PMCID: PMC10339256, DOI: 10.1016/j.jhepr.2023.100727.Peer-Reviewed Original ResearchRenal replacement therapy requirementAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityFurther prospective studiesMELD-NaTherapy requirementsProspective studyEnd-stage liver diseaseHigh short-term mortalityGlobal cohortRetrospective cohort studyCompeting-risk analysisTime-dependent AUCMELD-sodiumLiver transplantationMalnourished patientsCohort studyEstablishment of treatmentLiver diseaseABIC scoreLargest global cohortMAIN OUTCOMEMortality predictionDeLong method
2022
Role of Oral Health, Frailty, and Minimal Hepatic Encephalopathy in the Risk of Hospitalization: A Prospective Multi-Center Cohort of Outpatients With Cirrhosis
Bajaj J, Lai J, Tandon P, O'Leary J, Wong F, Garcia-Tsao G, Vargas H, Kamath P, Biggins S, Limon-Miro A, Shaw J, Mbachi C, Chew M, Golob Deeb J, Thacker L, Reddy K. Role of Oral Health, Frailty, and Minimal Hepatic Encephalopathy in the Risk of Hospitalization: A Prospective Multi-Center Cohort of Outpatients With Cirrhosis. Clinical Gastroenterology And Hepatology 2022, 21: 1864-1872.e2. PMID: 36328307, PMCID: PMC11057906, DOI: 10.1016/j.cgh.2022.10.023.Peer-Reviewed Original ResearchConceptsPoor oral healthOral healthMulti-center cohortCirrhosis detailsComorbid conditionsLiver diseaseEnd-stage liver diseaseMulti-center cohort studyRisk of hospitalizationPortal hypertensive complicationsMinimal hepatic encephalopathyNew study cohortMulti-variable analysisCirrhosis complicationsNonelective hospitalizationPeriodontitis historyPrior HEFrailty assessmentFrailty scoreHypertensive complicationsCohort studyHepatic encephalopathyStudy cohortRisk factorsCirrhosisAscites and its complications
Garcia‐Tsao G. Ascites and its complications. 2022, 522-531. DOI: 10.1002/9781119600527.ch59.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCirrhotic ascitesPresence of ascitesMainstay of therapySevere liver diseaseSpontaneous bacterial peritonitisAccumulation of fluidHepatorenal syndromePeritoneal malignancyUncomplicated ascitesAbdominal ultrasonographySodium restrictionCirrhotic patientsHepatic hydrothoraxBacterial peritonitisHeart failureLiver diseaseDecompensated stageCommon causePeritoneal cavityAscitesPatientsMost cost-effective methodBacterial infectionsCirrhosisCommon typePrognosis of hospitalized patients with cirrhosis and acute kidney disease
Wong F, Garcia‐Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS. Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International 2022, 42: 896-904. PMID: 35023264, PMCID: PMC11075740, DOI: 10.1111/liv.15154.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseStage 1 AKIAKD patientsPeak ScrAKI patientsCirrhotic patientsKidney diseaseSecond infectionEnd-stage liver diseaseDecompensated cirrhotic patientsHigher hospital admissionsWorse renal dysfunctionNormal renal functionGlomerular filtration rateNorth American ConsortiumBaseline SCrRenal dysfunctionPrompt treatmentRenal functionSerum creatinineHospital admissionClinical outcomesLiver diseasePredictive factorsFiltration rateClinical, histological and molecular profiling of different stages of alcohol-related liver disease
Ventura-Cots M, Argemi J, Jones PD, Lackner C, Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut 2022, 71: 1856-1866. PMID: 34992134, PMCID: PMC11034788, DOI: 10.1136/gutjnl-2021-324295.Peer-Reviewed Original ResearchConceptsAlcohol-related liver diseaseAlcohol-related hepatitisAH patientsLiver diseaseAlcohol intakeDuctular reactionGamma-glutamyl transferase levelsProfound liver failureSevere neutrophil infiltrationWorse liver functionObservational multicentre studyOne-year mortalityBile acid metabolismMallory-Denk bodiesRNA microarray analysisNeutrophil infiltrationProspective cohortRetrospective cohortAdvanced fibrosisLiver failureMulticentre studySteatosis gradeLiver functionPericellular fibrosisSevere fibrosis
2021
Baveno VII – Renewing consensus in portal hypertension
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Faculty B, Abraldes J, Albillos A, Baiges A, Bajaj J, Bañares R, Barrufet M, Benajiba L, Berzigotti A, Bureau C, Calvaruso V, Cardenas A, D’Amico G, De Gottardi A, Dell’Era A, Escorsell A, Fallowfield J, Ferral H, Francque S, Gaba R, Garcia-Pagàn J, Genescà J, Rodrigues S, Gracia-Sancho J, Han G, Hernandez-Gea V, Jia J, Kiladjian J, Krag A, Laleman W, La Mura V, Lens S, Luo X, Mandorfer M, Murad S, Paradis V, Patch D, Piano S, Pinzani M, Plessier A, Primignani M, Procopet B, Rautou P, Rudler M, Sarin S, Schepis F, Senzolo M, Shah V, Shukla A, Tandon P, Tellez L, Thabut D, Thiele M, Trebicka J, Tripathi D, Tsochatzis E, Turco L, Turon F, Valla D, Villanueva C, Wanless I, Yoshiji H. Baveno VII – Renewing consensus in portal hypertension. Journal Of Hepatology 2021, 76: 959-974. PMID: 35120736, PMCID: PMC11090185, DOI: 10.1016/j.jhep.2021.12.022.Peer-Reviewed Original ResearchConceptsPortal hypertensionAdvanced chronic liver diseaseHepatic venous pressure gradientAcute bleeding episodeSignificant portal hypertensionVenous pressure gradientChronic liver diseaseSplanchnic vein thrombosisCourse of cirrhosisRisk of deathNon-invasive toolBleeding episodesCompensated cirrhosisFurther decompensationVein thrombosisLiver diseaseBaveno VIVascular disordersFirst episodeHypertensionPersonalized careMedical literatureTherapeutic needsGold standardCirrhosisThe Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis
Musto JA, Eickhoff J, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Mathurin P, Garcia‐Tsao G, Schnabl B, Bataller R, Lucey MR. The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis. Liver Transplantation 2021, 27: 1382-1391. PMID: 34109723, PMCID: PMC11075741, DOI: 10.1002/lt.26203.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisAUDIT-C scoresMELD-NaAUDIT-10Recent alcohol consumptionAlcohol consumptionLiver injuryLiver diseaseSurvival statusAUDIT-ConsumptionEnd-stage liver diseaseAUDIT scoresAlcohol‐Associated HepatitisProspective international databaseMELD-Na scoreAlcohol Use Disorders Identification TestShort-term mortalityShort-term outcomesPrior yearDisorders Identification TestSeverity of drinkingPresenting featuresPrimary outcomeClinical outcomesClinical severityO-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES
Ragazzo T, Garcia-Tsao G, Mazo D, Ziteli P, Oliveira C, Singer J, Carrilho F, Pessoa M. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES. Annals Of Hepatology 2021, 24: 100493. DOI: 10.1016/j.aohep.2021.100493.Peer-Reviewed Original ResearchLiver stiffness measurementF3/F4Viral eliminationLiver fibrosisF0-1Advanced liver fibrosis/cirrhosisLiver fibrosis/cirrhosisChronic liver diseaseFibrosis/cirrhosisNon-invasive testsNon-invasive assessmentHCV cureAntiviral therapyClinical outcomesLiver diseaseHepatic fibrosisClinical usefulnessPatientsPredictive valueRelevant outcomesDecompensationLarger studyFibrosisLSM increaseStiffness measurementDiagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
Biggins SW, Angeli P, Garcia‐Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 74: 1014-1048. PMID: 33942342, DOI: 10.1002/hep.31884.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective studyVascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases
Northup PG, Garcia‐Pagan J, Garcia‐Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 73: 366-413. PMID: 33219529, DOI: 10.1002/hep.31646.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Intestinal Virome in Patients With Alcoholic Hepatitis
Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, Schwanemann LK, Ventura‐Cots M, Bataller R, Bosques‐Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia‐Tsao G, Kisseleva T, Brenner DA, Tu XM, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology 2020, 72: 2182-2196. PMID: 32654263, PMCID: PMC8159727, DOI: 10.1002/hep.31459.Peer-Reviewed Original ResearchConceptsAlcohol-associated liver diseaseAlcohol use disorderAlcoholic hepatitisDisease severityEnd-stage liver disease (MELD) scoreFecal samplesLiver Disease scoreMulticenter observational studyVirus-like particlesHigher median ModelIntestinal viromeLiver diseaseSevere manifestationsAntibiotic treatmentObservational studyDisease scoreUse disordersPatientsHigh mortalityViral diversityGut bacteriaViral microbiomeMortalitySeverityHepatitisClinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation
Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia‐Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation. Hepatology 2020, 72: 1819-1837. PMID: 32740969, PMCID: PMC7435542, DOI: 10.1002/hep.31491.Peer-Reviewed Original ResearchConceptsClinical researchInvestigational productAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicChronic liver diseaseLong-term followCoronavirus 2 pandemicClinical trial designImplementation of telemedicineHepatitis BLiver diseaseLaboratory monitoringClinical careTrial designCoronavirus disease 2019 (COVID-19) researchNatural historyCompletion of studyTherapeutic developmentNational InstituteCOVID-19 pandemicHepatologyOngoing studiesDiseaseIndustry fundingPandemic